BM
TERN

Bridger Management’s Terns Pharmaceuticals TERN Stock Holding History

Bridger Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-142,300
Closed -$1.19M – 33
2024
Q3 		$1.19M Sell
142,300
-104,500
-42% -$860K 0.59% 27
2024
Q2 		$1.68M Hold
246,800
– – 0.86% 22
2024
Q1 		$1.62M Buy
+246,800
New +$1.61M 0.73% 26

Other funds holding TERN

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bridger Management's TERN Position: Q4 2024 in Review

Bridger Management sold out of Terns Pharmaceuticals (TERN) in Q4 2024, closing a stake of 142,300 shares — an estimated $1.19M sold.

Bridger Management first reported a position in TERN in Q1 2024 and held it in 3 quarters. The position peaked at $1.68M in Q2 2024. 157 funds tracked by Wall St. Rank hold TERN as of Q4 2024.

  • Bridger Management reported no remaining Terns Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Bridger Management sold 142,300 Terns Pharmaceuticals shares in Q4 2024, an estimated $1.19M.
  • Bridger Management first reported a position in Terns Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Bridger Management's Terns Pharmaceuticals position peaked at $1.68M in Q2 2024.
  • 157 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q4 2024.

Based on Bridger Management's 13F filing for Q4 2024, filed 14 Feb 2025.